Paradigm Biocapital Advisors LP lessened its stake in shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN - Free Report) by 37.1% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund owned 1,820,079 shares of the company's stock after selling 1,075,610 shares during the period. Viridian Therapeutics comprises about 1.2% of Paradigm Biocapital Advisors LP's holdings, making the stock its 21st biggest position. Paradigm Biocapital Advisors LP owned about 2.30% of Viridian Therapeutics worth $34,891,000 as of its most recent filing with the SEC.
A number of other large investors have also added to or reduced their stakes in the stock. Loomis Sayles & Co. L P purchased a new position in Viridian Therapeutics in the 4th quarter valued at approximately $26,845,000. Price T Rowe Associates Inc. MD grew its stake in Viridian Therapeutics by 2,847.7% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 1,326,811 shares of the company's stock valued at $25,436,000 after buying an additional 1,281,799 shares in the last quarter. Deep Track Capital LP grew its stake in Viridian Therapeutics by 20.6% in the 4th quarter. Deep Track Capital LP now owns 4,522,741 shares of the company's stock valued at $86,701,000 after buying an additional 771,796 shares in the last quarter. FMR LLC grew its stake in Viridian Therapeutics by 6.2% in the 4th quarter. FMR LLC now owns 11,881,912 shares of the company's stock valued at $227,776,000 after buying an additional 698,434 shares in the last quarter. Finally, Parkman Healthcare Partners LLC grew its stake in Viridian Therapeutics by 155.9% in the 4th quarter. Parkman Healthcare Partners LLC now owns 1,087,634 shares of the company's stock valued at $20,850,000 after buying an additional 662,634 shares in the last quarter.
Viridian Therapeutics Price Performance
Shares of VRDN stock traded down $0.13 on Monday, hitting $12.81. 192,304 shares of the stock traded hands, compared to its average volume of 1,191,854. The firm has a market cap of $1.05 billion, a price-to-earnings ratio of -2.97 and a beta of 0.57. Viridian Therapeutics, Inc. has a 52 week low of $9.90 and a 52 week high of $27.20. The firm has a 50 day simple moving average of $13.41 and a two-hundred day simple moving average of $17.10. The company has a debt-to-equity ratio of 0.04, a current ratio of 18.55 and a quick ratio of 18.55.
Viridian Therapeutics (NASDAQ:VRDN - Get Free Report) last announced its quarterly earnings results on Tuesday, May 6th. The company reported ($0.87) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.95) by $0.08. The company had revenue of $0.07 million for the quarter, compared to the consensus estimate of $0.16 million. Viridian Therapeutics had a negative net margin of 85,127.16% and a negative return on equity of 70.12%. The firm's quarterly revenue was up .0% on a year-over-year basis. As a group, equities research analysts predict that Viridian Therapeutics, Inc. will post -4.03 earnings per share for the current fiscal year.
Analyst Upgrades and Downgrades
A number of equities analysts have recently commented on the stock. Royal Bank of Canada cut their price objective on shares of Viridian Therapeutics from $46.00 to $45.00 and set an "outperform" rating for the company in a research report on Wednesday, May 7th. JMP Securities cut their target price on shares of Viridian Therapeutics from $42.00 to $38.00 and set a "market outperform" rating for the company in a research report on Wednesday, May 7th. The Goldman Sachs Group cut their target price on shares of Viridian Therapeutics from $31.00 to $27.00 and set a "buy" rating for the company in a research report on Wednesday, May 7th. HC Wainwright reiterated a "buy" rating and issued a $34.00 target price on shares of Viridian Therapeutics in a research report on Wednesday, April 23rd. Finally, Needham & Company LLC cut their target price on shares of Viridian Therapeutics from $38.00 to $36.00 and set a "buy" rating for the company in a research report on Wednesday, May 7th. One investment analyst has rated the stock with a hold rating and ten have assigned a buy rating to the company's stock. According to MarketBeat.com, Viridian Therapeutics presently has an average rating of "Moderate Buy" and an average target price of $36.70.
Read Our Latest Report on VRDN
Viridian Therapeutics Profile
(
Free Report)
Viridian Therapeutics, Inc, a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED.
Further Reading
Before you consider Viridian Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Viridian Therapeutics wasn't on the list.
While Viridian Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.
Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
